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The development of immune-based treatment (immunotherapy) for childhood cancer 
is a rapidly advancing field with impressive results already achieved in children with 
leukaemia.1 2  For cancers resistant to conventional treatments, harnessing the 
power and specificity of the immune system to fight cancer is an attractive alternative 
approach. The immune system is essential for controlling cancer progression by 
continual surveillance and elimination of transformed cells. This protective process is 
hindered by the ability of cancer cells to develop mechanisms enabling them to ‘hide’ 
from immune destruction (including down-regulation of tumour-associated antigens 
and major histocompatibility complex (MHC) class I, and the creation of an 
immunosuppressive tumour microenvironment).  The aims of cancer immunotherapy 
are to enhance existing anti-tumour immune responses (active immunotherapy), 
including cancer vaccines and immune check-point inhibitors, or to enable the 
immune system to specifically recognise and kill cancer cells (passive 
immunotherapy) (Table 1).   
 
 
Passive immunotherapy Active immunotherapy 
Monoclonal antibodies Cancer vaccines 
Bispecific antibodies Immune check-point inhibitors 
CAR T-cells  
TCR-redirected T-cells  
Tumour infiltrating lymphocytes   
Viral reactive T-cells  
Donor lymphocytes  
 
 
Table 1. Classification of immune-based therapies for childhood cancer.  
Abbreviations: CAR; chimeric antigen receptor, TCR; T-cell receptor. 
The identification of targetable tumour antigens is fundamental to the development of 
successful ‘passive’ immunotherapies.  Ideally targets should be highly expressed on 
cancer cells with little or no expression on normal tissue in order to avoid the 
potential for ‘on-target, off-tumour’ toxicities. B-lymphocyte antigen CD19 and 
disialoganglioside GD2 have been selected as suitable antigens for paediatric 
leukaemia and neuroblastoma immunotherapy clinical trials, respectively.1 3 
However, neither of these targets are 100% perfect as CD19-directed therapy 
causes depletion of healthy B-cells, and GD2 is expressed at low level on normal 
peripheral nerves.   
 
This article gives a brief overview of the main types of immunotherapy currently 
under development (Table 2), and addresses some of the main caveats surrounding 
translation to clinical practice.   
  
 
Immunotherapy  Description Advantages Limitations 
Monoclonal 
antibodies (MAb) 
Bind tumour antigen and augment 
antibody-dependent cell-mediated 
cytotoxicity (ADCC) e.g. anti-GD2 
(Ch14.18)3 and anti-CD20 
(rituximab)4.  MAb can also be linked 
to chemotherapeutics or 
radionuclides.   
‘Off the shelf’ product 
Efficacious in Phase III 
clinical trials 
 
Short half-life, requires repeated 
administration 
‘On target, off tumour’ side effects 
Anaphylactoid reactions 
Bispecific antibodies Simultaneously bind tumour antigen 
and T-cell e.g. blinatumomab5 binds 
CD19 and CD3 
‘Off the shelf’ product 
 
Short half-life, requires repeated 
administration 
Cytokine release syndrome 
Potential for ‘antigen escape’ 
Checkpoint inhibitors e.g. anti-PD-1 or anti-CTLA-4 
(Ipilimumab) antibodies block 
inhibitory immune signals 
‘Off the shelf’ product Short half-life, requires repeated 
administration 
Cytokine release syndrome 
Tumour vaccines Most commonly Ex vivo production of 
autologous tumour antigen pulsed 
dendritic cells for injection 
Generation of 
immunological memory 
Patient specific therefore expensive to 




T-cells are extracted from the tumour 
itself and cultured ex vivo to large 




Not reliably produced from all tumour 
samples 
Limited study in paediatric patients 
 
Viral reactive T-cells T-cells stimulated with viral antigen 
expressing antigen presenting cells 
Immunological memory Patient specific 
Small number of cells for infusion 
 
TCR re-directed T 
cells 
Autologous T-cells are genetically 
modified with tumour antigen specific 
T-cell receptors  
Immunological memory 
Directly target tumour 
antigen 




Risk of mis-pairing with endogenous 
TCR 
Cytokine release syndrome 
 
CAR re-directed T 
cells 
Autologous T-cells are genetically 
modified with  
Chimeric antigen receptors 
Immunological memory 
Can include ‘safety switch’ 
 MHC-unrestricted 
Can be engineered with 
‘costimulatory’ domains to 




Can only target known cell surface 
antigens 
Cytokine release syndrome 
‘On-target, Off tumour’ side effects 
Potential for ‘antigen escape’ 
 
 
Table 2. Overview of cancer immunotherapy approaches.  
Abbreviations: ALL; Acute Lymphoblastic Leukaemia, CNS; central nervous system, 
EBV; Epstein-Barr virus, CAR; chimeric antigen receptor, TCR; T-cell receptor, 




WHAT TYPES OF CANCER IMMUNOTHERAPY ARE BEING DEVELOPED? 
 
Monoclonal antibodies 
Over the last two decades, the development of monoclonal antibodies to treat cancer 
has yielded some of the greatest successes. Monoclonal antibodies directly targeting 
tumour antigens have now been incorporated into many standard paediatric 
treatment protocols3.  Bispecific antibodies and bispecific T-cell engagers (BiTE) 
bind two targets and can therefore simultaneously bind a tumour antigen and 
cytotoxic T-cell.5 
 
Antibodies have also been engineered to block immune check-points.  PD-1 and 
CTLA-4 are examples of inhibitory co-receptors that provide an ‘immunological 
break’ to uncontrolled T-cell activation.  Monoclonal antibodies that target these 
checkpoints can augment existing inhibited immune responses to cancer.  PD-1 
blockade has shown great promise in clinical trials for metastatic melanoma6 and 
other adult cancers, and its efficacy is now being tested in paediatric malignancies. 
 
Adoptive cell therapy  
Adoptive cell therapy (ACT) is an example of ‘personalised medicine’ where 
autologous tumour specific T-cells are manufactured in the laboratory before re-
infusion back into the patient. Approaches in children include the culturing and 
genetic modification of T-cells to promote activation, proliferation and tumour 
specificity (Figure 1).  
 
Tumour specificity of T-cells from peripheral blood can be achieved by genetic 
modification with antigen-specific T-cell receptors (TCRs) or chimeric antigen 
receptors (CARs).  CARs combine an extracellular antibody-derived antigen-binding 
domain with an intracellular T-cell activation domain (Figure 1). CARs have the 
additional advantage of being unrestricted by MHC, unlike TCRs.   
 
Clinical trials using CD19-directed CAR T-cells for children with refractory leukaemia 
have achieved greater than 70% remission rates.1  A research priority is now to 
translate expertise to solid tumours and a key challenge will be engineering CAR T-
cells that effectively traffic to tumour sites, and form immunological memory. 
 
Naturally occurring tumour-reactive T-cells can also be derived and propagated from 
tumour tissue itself under special culture conditions (known as tumour infiltrating 
lymphocytes, TILs), although there has been little clinical experience to date for 
childhood solid tumours. 
 
Cancer vaccines 
An example of active immunotherapy is through vaccination, however clinical trials 
aimed at inducing anti-tumour immune responses have so far been disappointingly 
ineffective in children with cancer. 
 
 
TRANSLATING IMMUNOTHERAPY INTO CLINICAL PRACTICE 
 
The development of novel immunotherapies must include rigorous pre-clinical testing 
to fully assess any potential harm to patients. Toxicities can be divided into two 
groups; those related to autoimmunity (‘on-target, off tumour effects’) and those 
relating to an increase in circulating cytokines (e.g. leading to cytokine-release 
syndrome).7  Learning how to recognise and manage these toxicities will be key 
following translation to large-scale clinical trials. 
 
The manufacture of a personalised immunotherapeutic is a highly complex and 
labour-intensive process that is currently restricted to just a few centres in the UK. 
Hence, currently treatment is limited to a small number of patients within a clinical 
trial setting. CD19 CAR T-cells however are now being commercialised for much 
wider application and one exciting development is ‘off the shelf’ rather than ‘patient-
specific’ therapies achievable through “genome editing” in which third party donor 




There has been a paradigm shift in adult oncology through the developments of 
cancer immunotherapy. For paediatrics, a major rate-limiting step has been the 
identification of optimal targetable tumour antigens. Combinational therapies with 
standard treatments or other immune-based treatments to overcome the 
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Figure 1 – Production of autologous chimeric antigen receptor (CAR) engineered T-
cells for patient infusion.   
 
